HIV Vaccine Approved for Clinical Trials

Beverly Merz
JAMA. 1987;258(11):1433-1434. doi:10.1001/jama.1987.03400110013003.
Text Size: A A A
Published online


THE FIRST CLINICAL TRIALS in the United States of a vaccine against human immunodeficiency virus (HIV) are slated to begin this month.

The Food and Drug Administration (FDA) approved the vaccine, registered as VaxSyn HIV-1 by the manufacturer, MicroGeneSys, Inc, West Haven, Conn, for investigational use Aug 18. It is one of several HIV vaccines in various stages of development in this country. At least three other efforts—by Genentech, San Francisco; two Seattle-based firms, Genetic Systems and a Bristol-Myers subsidiary, Oncogen; and the Institute of Immunological Disorders, Houston—may see vaccines reach clinical trials by year's end.

VaxSyn HIV-1, a recombinant form of the HIV envelope protein gp 160, is the product of a collaboration between Micro Gene Sys (pronounced "microgenesis") and investigators at the National Institute of Allergy and Infectious Diseases (NIAID). MicroGeneSys holds the patent on the vaccine and will pay royalties to the federal government should the vaccine eventually be marketed.


Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours




Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.